Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival

BMC Clinical Pathology

Stamatios Theocharis¹  Efstratios Patsouris¹  Nikolaos Kavantzas¹  Paraskevi Alexandrou¹  Evangelos Bournakis²  Nikolaos Tsoukalas²  Constantinos Giaginis³ 

[1] First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 75 M. Asias str., Goudi, Athens GR11527, Greece;Department of Medical Oncology, 401 General Military Hospital, Athens, Greece;Department of Food Science and Nutrition, School of the Environment, University of the Aegean, Myrina Lemnos, Greece

关键词: Immunohistochemistry;    Prognosis;    Clinicopathological parameters;    Non-small cell lung carcinoma;    Ephrin receptors;   

Others  :  1216147
DOI  :  10.1186/1472-6890-14-8

 received in 2013-03-30, accepted in 2014-01-27,  发布年份 2014

【 摘 要 】

Background

Ephrin (Eph) receptors are frequently overexpressed in a wide variety of human malignant tumors, being associated with tumor growth, invasion, metastasis and angiogenesis. The present study aimed to evaluate the clinical significance of EphA1, A4, A5 and A7 protein expression in non-small cell lung carcinoma (NSCLC).

Methods

EphA1, A4, A5 and A7 protein expression was assessed immunohistochemically in tissue microarrays of 88 surgically resected NSCLC and was analyzed in relation with clinicopathological characteristics and patients’ survival.

Results

Elevated EphA4 expression was significantly associated with low histopathological stage and presence of inflammation (p = 0.047 and p = 0.026, respectively). Elevated EphA7 expression was significantly associated with older patients’ age, presence of fibrosis and smaller tumor size (p = 0.036, p = 0.029 and p = 0.018, respectively). EphA1, A5 and A7 expression were positively associated with tumor proliferative capacity (p = 0.047, p = 0.002 and p = 0.046, respectively). Elevated EphA4, A5 and A7 expression were identified as predictors of favourable patients’ survival at both univariate (Log-rank test, 0 = 0.019, p = 0.006 and p = 0.012, respectively) and multivariate levels (Cox-regression analysis, p = 0.029, p = 0.068 and p = 0.044, respectively).

Conclusions

The present study supported evidence that Ephs may be involved in lung cancer progression, reinforcing their utility as clinical biomarkers for patients’ management and prognosis, as also as potential targets for future therapeutic interventions.

【 授权许可】

   
2014 Giaginis et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Zhang J, Hughes SE: Role of the ephrin and Ephrin receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol 2006, 208:453-461.
• [2]Pasquale EB: Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008, 133:38-52.
• [3]Nakamoto M, Bergemann AD: Diverse role for the Eph family of receptor tyrosine kinases in carcinogenesis. Microscopy Res Technique 2002, 59:58-67.
• [4]Surawska H, Ma PC, Salgia R: The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 2004, 15:419-433.
• [5]Vearing CJ, Lackmann M: Eph receptor signalling; dimerisation just isn't enough. Growth Factors 2005, 23:67-76.
• [6]Cheng N, Brantley DM, Chen J: The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 2002, 13:75-85.
• [7]Brandley-Sieders DM, Chen J: Eph receptor tyrosine kinase in angiogenesis: From development to disease. Angiogenesis 2007, 7:17-28.
• [8]Castaño J, Davalos V, Schwartz S Jr, et al.: EPH receptors in cancer. Histol Histopathol 2008, 23:1011-1023.
• [9]Pasquale EB: Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010, 10:165-180.
• [10]Nievergall E, Lackmann M, Janes PW: Eph-dependent cell-cell adhesion and segregation in development and cancer. Cell Mol Life Sci 2012, 69:1813-1842.
• [11]Xi HQ, Wu XS, Wei B, Chen L: Eph receptors and ephrins as targets for cancer therapy. J Cell Mol Med 2012, 16:2894-2909.
• [12]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
• [13]D' Addario G, Felip E: Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20:68-70.
• [14]Alberg AJ, Brock MV, Samet JM: Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005, 23:3175-3185.
• [15]Méndez D, Alshanqeety O, Warner KE, Lantz PM, Courant PN: The impact of declining smoking on radon-related lung cancer in the United States. Am J Public Health 2011, 101:310-314.
• [16]Brantley-Sieders DM, Jiang A, Sarma K, et al.: Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS One 2011, 6:e24426.
• [17]Brantley-Sieders DM: Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling. Semin Cell Dev Biol 2012, 23:102-108.
• [18]Giaginis C, Tsourouflis G, Zizi-Serbetzoglou A, et al.: Clinical significance of Ephrin (Eph)-A1, -A2, -A4, -A5 and -A7 receptors in pancreatic ductal adenocarcinoma. Pathol Oncol Res 2010, 16:267-276.
• [19]Karidis NP, Giaginis C, Tsourouflis G, et al.: Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: an immunohistochemical study. Med Sci Monit 2011, 17:BR257-BR265.
• [20]Greene FLPD, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M: AJCC cancer staging manual. 6th edition. New York: Springer-Verlag; 2002.
• [21]Nair A, Klusmann MJ, Jogeesvaran KH, et al.: Revisions to the TNM Staging of Non-Small Cell Lung Cancer: Rationale, Clinicoradiologic Implications, and Persistent Limitations. Radiographics 2011, 31:215-238.
• [22]Lababede O, Meziane M, Rice T: Seventh edition of the cancer staging manual and stage grouping of lung cancer: quick reference chart and diagrams. Chest 2011, 139:183-189.
• [23]Giaginis C, Politi E, Alexandrou P, et al.: Expression of peroxisome proliferator activated receptor-gamma (PPAR-γ) in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival. Pathol Oncol Res 2012, 18:875-883.
• [24]Dong Y, Wang J, Sheng Z, et al.: Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis. Mod Pathol 2009, 22:151-160.
• [25]Abraham S, Knapp DW, Cheng L, et al.: Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 2006, 12:353-360.
• [26]Holm R, Knopp S, Suo Z, et al.: Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis. J Clin Pathol 2007, 60:1086-1091.
• [27]Hafner C, Becker B, Landthaler M, Vogt T: Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol 2006, 19:1369-1377.
• [28]Li JJ, Xie D: The roles and therapeutic potentials of Ephs and ephrins in lung cancer. Exp Cell Res 2013, 319:152-159.
• [29]Brannan JM, Dong W, Prudkin L, et al.: Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 2009, 15:4423-4430.
• [30]Kinch MS, Moore MB, Harpole DH Jr: Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 2003, 9:613-618.
• [31]Ishikawa M, Miyahara R, Sonobe M, et al.: Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. Lung Cancer 2012, 76:431-438.
• [32]Saintigny P, Peng S, Zhang L, et al.: Global Evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Mol Cancer Ther 2012, 11:2021-2032.
• [33]Yu J, Bulk E, Ji P, et al.: The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer. Clin Cancer Res 2010, 16:2275-2283.
• [34]Ding L, Getz G, Wheeler DA, et al.: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
• [35]Zheng MF, Ji Y, Wu XB, et al.: EphB4 gene polymorphism and protein expression in non-small-cell lung cancer. Mol Med Report 2012, 6:405-408.
• [36]Tandon M, Vemula SV, Mittal SK: Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets 2011, 15:31-51.
• [37]Kandouz M: The Eph/Ephrin family in cancer metastasis: communication at the service of invasion. Cancer Metastasis Rev 2012, 31:353-373.
• [38]Landen CN Jr, Chavez-Reyes A, Bucana C, et al.: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005, 65:6910-6918.
• [39]Shahzad MM, Lu C, Lee JW, et al.: Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 2009, 8:1027-1034.
• [40]Zhuang G, Brantley-Sieders DM, Vaught D, et al.: Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 2010, 70:299-308.
• [41]Larsen AB, Pedersen MW, Stockhausen MT, et al.: Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res 2007, 5:283-293.
• [42]Tsuboi M, Mori H, Bunai T, et al.: Secreted form of EphA7 in lung cancer. Int J Cancer 2010, 36:635-640.